LUNG CANCER
Latest News
June 20th 2017
By Ariela Katz
The risk of disease progression was reduced by more than 40% and there was an average 6.5-month improvement in response duration with the second-generation EGFR inhibitor dacomitinib compared with gefitinib as a first-line treatment for patients with advanced, <em>EGFR</em>-mutant non–small cell lung cancer.
Latest Videos
CME Content
More News
Treatment with nintedanib plus pemetrexed and cisplatin improved progression-free survival (PFS) in the frontline setting by 3.7 months for chemotherapy-naive patients with malignant pleural mesothelioma.
Second-generation ALK inhibitor alectinib (Alecensa) demonstrated a 15-month improvement in progression-free survival compared with crizotinib (Xalkori), the first-generation ALK inhibitor and standard of care, in patients with <em>ALK</em>-positive non–small cell lung cancer.
It’s been a busy month at the FDA. Here’s a look back at all the news in the oncology field to come out of the FDA during the month of May.
Updates to the NCCN guidelines for the management of advanced NSCLC stress the importance of multiplexed biomarker testing at diagnosis to aid in the selection of appropriate first-line and subsequent lines of therapy.
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Ceritinib (Zykadia) has been approved by the FDA for the treatment of patients with <em>ALK</em>-positive, metastatic non–small cell lung cancer.
NSCLC with Multiple Sites of Metastasis and No Driver Mutation
Metastatic Lung Adenocarcinoma Without a Driver Mutation
Anna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.
Durvalumab (Imfinzi) showed a modest but encouraging clinical benefit in patients with <em>EGFR</em>-mutant or <em>ALK</em>-positive non–small cell lung cancer with high tumor PD-L1 expression of ≥25% in the third-line setting or beyond.
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).